Evidence map›Paper›PMID 29769046›Full record

ArticleBMC cancer2018

γ-Tocotrienol induces apoptosis in pancreatic cancer cells by upregulation of ceramide synthesis and modulation of sphingolipid transport.

Victoria E Palau, Kanishka Chakraborty, Daniel Wann, Janet Lightner, Keely Hilton, Marianne Brannon, William Stone, Koyamangalath Krishnan

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Significance of Vitamins A and E in Cancer Progression and Prevention.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Vitamin E in the management of pancreatic cancer: A scoping review.World journal of gastrointestinal oncology · 2023
    Article
  5. Article
  6. Ceramide Transfer Protein (CERT): An Overlooked Molecular Player in Cancer.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Victoria E PalauDivision of Hematology-Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Kanishka ChakrabortyDivision of Hematology-Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Daniel WannDepartment of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Janet LightnerDivision of Hematology-Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Keely HiltonDivision of Hematology-Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Marianne BrannonDepartment of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
William StoneDepartment of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Koyamangalath KrishnanDivision of Hematology-Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA. krishnak@etsu.edu.ORCID http://orcid.org/0000-0002-6342-4412
East Tennessee State University · USBeth Israel Deaconess Medical Center · US

Funding

Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
East Tennessee State University Dishner Chair of ExcellenceNCATS NIH HHS UL1 TR000040
6 · The paper itself

Abstract

backgroundCeramide synthesis and metabolism is a promising target in cancer drug development. γ-tocotrienol (GT3), a member of the vitamin E family, orchestrates multiple effects that ensure the induction of apoptosis in both, wild-type and RAS-mutated pancreatic cancer cells. Here, we investigated whether these effects involve changes in ceramide synthesis and transport.

methodsThe effects of GT3 on the synthesis of ceramide via the de novo pathway, and the hydrolysis of sphingomyelin were analyzed by the expression levels of the enzymes serine palmitoyl transferase, ceramide synthase-6, and dihydroceramide desaturase, and acid sphingomyelinase in wild-type RAS BxPC3, and RAS-mutated MIA PaCa-2 and Panc 1 pancreatic cancer cells. Quantitative changes in ceramides, dihydroceramides, and sphingomyelin at the cell membrane were detected by LCMS. Modulation of ceramide transport by GT3 was studied by immunochemistry of CERT and ARV-1, and the subsequent effects at the cell membrane was analyzed via immunofluorescence of ceramide, caveolin, and DR5.

resultsGT3 favors the upregulation of ceramide by stimulating synthesis at the ER and the plasma membrane. Additionally, the conversion of newly synthesized ceramide to sphingomyelin and glucosylceramide at the Golgi is prevented by the inhibition of CERT. Modulation ARV1 and previously observed inhibition of the HMG-CoA pathway, contribute to changes in membrane structure and signaling functions, allows the clustering of DR5, effectively initiating apoptosis.

conclusionsOur results suggest that GT3 targets ceramide synthesis and transport, and that the upregulation of ceramide and modulation of transporters CERT and ARV1 are important contributors to the apoptotic properties demonstrated by GT3 in pancreatic cancer cells.

Indexed as

Antineoplastic AgentsApoptosisCarrier ProteinsCeramidesChromansDrug Screening Assays, AntitumorHumansMembrane ProteinsPancreatic NeoplasmsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)SphingolipidsUp-RegulationVitamin EAntineoplastic AgentsARV1 protein, humanCarrier ProteinsCeramidesCERT1 protein, humanChromansKRAS protein, humanMembrane Proteinsplastochromanol 8Protein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)SphingolipidsVitamin EARV-1Ceramide distributionCeramide synthesisCeramide transportCERTFree radicalsLipid transportMembrane lipidPancreatic cancerVitamin Eγ-Tocotrienol

Identifiers

PMID29769046
PMCPMC5956825
OpenAlexW2806322672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.